Jabre Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jabre Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-30,000	Closed	-$2.83M	–	146
2018 Q2	$2.83M	Buy	+30,000	New	+$2.63M	0.19%	47
2017 Q4	–	Sell	-45,000	Closed	-$4.19M	–	107
2017 Q3	$4.19M	Buy	+45,000	New	+$3.98M	0.81%	52
2015 Q2	–	Sell	-35,000	Closed	-$4.07M	–	101
2015 Q1	$4.07M	Buy	+35,000	New	+$3.71M	0.38%	70
2014 Q4	–	Sell	-75,000	Closed	-$4.98M	–	106
2014 Q3	$4.98M	Sell	75,000 -731,355	-91%	-$48.1M	0.43%	70
2014 Q2	$50.2M	Buy	806,355 +540,855	+204%	+$32.7M	3.53%	4
2014 Q1	$16.9M	Buy	+265,500	New	+$19.6M	1.62%	20

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jabre Capital Partners's BMRN Position: Q3 2018 in Review

Jabre Capital Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2018, closing a stake of 30,000 shares — an estimated $2.83M sold.

Jabre Capital Partners first reported a position in BMRN in Q1 2014 and held it in 6 quarters. The position peaked at $50.2M in Q2 2014. 459 funds tracked by Wall St. Rank hold BMRN as of Q3 2018.

Jabre Capital Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Jabre Capital Partners sold 30,000 BioMarin Pharmaceuticals shares in Q3 2018, an estimated $2.83M.
Jabre Capital Partners first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Jabre Capital Partners's BioMarin Pharmaceuticals position peaked at $50.2M in Q2 2014.
459 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2018.

Based on Jabre Capital Partners's 13F filing for Q3 2018, filed 14 Nov 2018.